Investor Overview

Synta Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. Synta has a unique chemical compound library, an integrated discovery engine, and a pipeline of small molecule drug candidates with novel chemical structures and distinct mechanisms of action. All clinical candidates were invented internally by Synta scientists using our compound library and discovery capabilities. Our lead clinical candidate, elesclomol, is in a global, pivotal, Phase 3 clinical trial for... More >>

Date Title   11/20/08 Synta Pharmaceuticals Announces First Patient Treated in Phase 1/2 Clinical Trial of Elesclomol in Prostate Cancer LEXINGTON, Mass., Nov 20, 2008 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp., (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the first patient has been treated in its Phase 1/2 clinical study for its novel oxidative stress inducer, elesclomol, in combination with docetaxel in metastatic, hormone refractory prostate cancer. Elesclom...  11/13/08 Synta Pharmaceuticals Reports Third Quarter 2008 Financial Results LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 13, 2008--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended September 30, 2008. In the third quarter of 2008, the Company recorded $1.3 million of net collaboration revenue under its partnership agreement with GlaxoSmithKline (GSK). The Company reported a...  11/12/08 Synta Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Conference Company to Webcast Presentation on November 19 LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 12, 2008--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Company will be presenting at the Lazard Capital Markets Healthcare Conference on Wednesday, November 19 at 2:00 p.m. (ET) at The St. Regis in New York. A live audio webcast...